Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Avoralstat · BCX-4161

Small molecule · developed by BioCryst Pharmaceuticals

Phase 3 Most advanced trial (none active)
BCRX Developer
2 Registered trials

What is Avoralstat?

Avoralstat (BCX4161, BCX-4161) is a small molecule studied in hereditary angioedema, a condition marked by recurrent swelling attacks.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
BCX-4161
Drug type
Small molecule
Therapy area
Immunology
Developer
BioCryst Pharmaceuticals (BCRX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
UX17773O15

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02670720 Phase 3 Hereditary Angioedema Terminated BCRX
NCT02303626 Phase 2/3 Hereditary Angioedema Completed BCRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HAEHereditary Angioedema

More from BioCryst Pharmaceuticals

Berotralstat FDA approved Peramivir FDA approved BCX10013 Phase 1 BCX17725 Phase 1 Forodesine Phase 1/2 Galidesivir Phase 1 Pelecopan Phase 2 Ulodesine Phase 2

Follow BCRX, the company behind Avoralstat

See BCRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BCRX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.